FDA Guidances Part of Charm Offensive to Woo Compounders

Drug Industry Daily
A A
The flurry of FDA guidance issued this week explaining to compounders how to work with the FDA is part of the agency’s full-on effort to make registration as appealing as possible to compounders who may worry that regulatory oversight will hamper business.

To View This Article:

Login

Subscribe To Drug Industry Daily